Likewise, STAT1 upregulation has been reported in resistance to doxorubicin, cisplatin, and docetaxel in ovarian and prostate cancer [6,177], while, in lung cancer, STAT1-dependent association with HDAC4 and the subsequent STAT1-driven upregulation of the multidrug resistance 1 (Mrd1) gene, has been linked to the failure of the topoisomerase II inhibitor, etoposide [232]. This evidence concerns the gene STAT1 and prostate cancer.